O
VRTX icon

OppenheimerFunds’s Vertex Pharmaceuticals VRTX Stock Holding History

OppenheimerFunds’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$84.2M Sell
457,794
-10,786
-2% -$1.99M 0.1% 202
2018
Q4 		$77.6M Sell
468,580
-47,649
-9% -$8.26M 0.11% 188
2018
Q3 		$99.5M Sell
516,229
-7,086
-1% -$1.26M 0.12% 195
2018
Q2 		$88.9M Buy
523,315
+462,000
+753% +$71.6M 0.11% 212
2018
Q1 		$9.99M Buy
61,315
+58,508
+2,084% +$9.56M 0.01% 692
2017
Q4 		$421K Buy
2,807
+694
+33% +$103K ﹤0.01% 1578
2017
Q3 		$321K Sell
2,113
-305
-13% -$45.9K ﹤0.01% 1693
2017
Q2 		$312K Sell
2,418
-344,597
-99% -$41.5M ﹤0.01% 1696
2017
Q1 		$37.9M Sell
347,015
-191,087
-36% -$16.8M 0.05% 388
2016
Q4 		$39.6M Sell
538,102
-1,024,156
-66% -$83.3M 0.05% 379
2016
Q3 		$136M Buy
1,562,258
+219,382
+16% +$20.7M 0.17% 151
2016
Q2 		$116M Buy
1,342,876
+107,571
+9% +$9.29M 0.15% 165
2016
Q1 		$98.2M Buy
1,235,305
+219,120
+22% +$19.8M 0.13% 190
2015
Q4 		$128M Buy
1,016,185
+64,261
+7% +$7.76M 0.16% 153
2015
Q3 		$99.1M Sell
951,924
-737,088
-44% -$94.7M 0.13% 186
2015
Q2 		$209M Sell
1,689,012
-205,550
-11% -$25.9M 0.24% 113
2015
Q1 		$224M Sell
1,894,562
-538,060
-22% -$64.5M 0.25% 112
2014
Q4 		$289M Buy
2,432,622
+34,490
+1% +$3.88M 0.32% 93
2014
Q3 		$269M Buy
2,398,132
+97,250
+4% +$9.26M 0.3% 89
2014
Q2 		$218M Sell
2,300,882
-1,183,435
-34% -$83M 0.24% 115
2014
Q1 		$246M Sell
3,484,317
-124,560
-3% -$9.87M 0.29% 90
2013
Q4 		$268M Buy
3,608,877
+67,520
+2% +$4.7M 0.33% 76
2013
Q3 		$269M Sell
3,541,357
-18,250
-0.5% -$1.45M 0.36% 73
2013
Q2 		$284M Buy
+3,559,607
New +$262M 0.41% 55

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

OppenheimerFunds's VRTX Position: Q1 2019 in Review

OppenheimerFunds reduced its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q1 2019, selling an estimated $1.99M and leaving 457,794 shares worth $84.2M. The position accounts for 0.1% of the portfolio, ranked #202.

OppenheimerFunds first reported a position in VRTX in Q2 2013 and has held it in 24 quarters since. The position peaked at $289M in Q4 2014. 736 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

  • OppenheimerFunds held 457,794 shares of Vertex Pharmaceuticals worth $84.2M as of Q1 2019.
  • OppenheimerFunds sold 10,786 Vertex Pharmaceuticals shares in Q1 2019, an estimated $1.99M.
  • Vertex Pharmaceuticals made up 0.1% of OppenheimerFunds's portfolio in Q1 2019, its #202 holding.
  • OppenheimerFunds first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • OppenheimerFunds's Vertex Pharmaceuticals position peaked at $289M in Q4 2014.
  • 736 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.